JP2012067110A5 - - Google Patents

Download PDF

Info

Publication number
JP2012067110A5
JP2012067110A5 JP2011233850A JP2011233850A JP2012067110A5 JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5 JP 2011233850 A JP2011233850 A JP 2011233850A JP 2011233850 A JP2011233850 A JP 2011233850A JP 2012067110 A5 JP2012067110 A5 JP 2012067110A5
Authority
JP
Japan
Prior art keywords
use according
chlorite
disorder
tcdo
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011233850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012067110A (ja
JP5797083B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012067110A publication Critical patent/JP2012067110A/ja
Publication of JP2012067110A5 publication Critical patent/JP2012067110A5/ja
Application granted granted Critical
Publication of JP5797083B2 publication Critical patent/JP5797083B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011233850A 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸 Expired - Lifetime JP5797083B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54157604P 2004-02-03 2004-02-03
US60/541,576 2004-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006552151A Division JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015118841A Division JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Publications (3)

Publication Number Publication Date
JP2012067110A JP2012067110A (ja) 2012-04-05
JP2012067110A5 true JP2012067110A5 (enExample) 2013-04-04
JP5797083B2 JP5797083B2 (ja) 2015-10-21

Family

ID=34860199

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸
JP2011233850A Expired - Lifetime JP5797083B2 (ja) 2004-02-03 2011-10-25 神経変性疾患の処置における亜塩素酸
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006552151A Expired - Lifetime JP5072367B2 (ja) 2004-02-03 2005-01-25 神経変性疾患の処置における亜塩素酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015118841A Pending JP2015205901A (ja) 2004-02-03 2015-06-12 神経変性疾患の処置における亜塩素酸

Country Status (7)

Country Link
US (5) US7105183B2 (enExample)
EP (2) EP1711191B1 (enExample)
JP (3) JP5072367B2 (enExample)
CN (2) CN102423318B (enExample)
AU (1) AU2005213300B2 (enExample)
CA (2) CA2838392C (enExample)
WO (1) WO2005076819A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006009506A1 (en) * 2004-07-16 2006-01-26 Gyros Patent Ab Sequential method
MX2007013985A (es) 2005-05-09 2008-02-22 Theranos Inc Sistemas de fluidos de punto de cuidado y usos de los mismos.
DK1915620T3 (da) * 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US8067035B2 (en) 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
AU2013234421B2 (en) * 2005-12-22 2015-08-27 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US8007999B2 (en) * 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
EA201290041A1 (ru) * 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
AU2010308329B2 (en) 2009-10-19 2016-10-13 Labrador Diagnostics Llc Integrated health data capture and analysis system
EP2545381A1 (en) * 2010-03-10 2013-01-16 Yeda Research And Development Co. Ltd. Cellular blood markers for early diagnosis of als and for als progression
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
KR101847669B1 (ko) * 2010-08-16 2018-05-24 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
CN107759690A (zh) * 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA2945179A1 (en) * 2014-05-16 2015-11-19 Michael S. Mcgrath Methods and compositions for treatment of macrophage-related disorders
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
JP2025518546A (ja) * 2022-05-19 2025-06-17 ニューヴィヴォ， インコーポレイテッド 神経変性疾患のバイオマーカー
US20250114396A1 (en) * 2023-07-07 2025-04-10 The Regents Of The University Of California Chlorite uses for stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (de) * 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US5051414A (en) * 1989-08-03 1991-09-24 Dupont Merck Pharmaceutical Company Inhibition of HIV and other retroviruses by polyoxoanions
DE4208828A1 (de) 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
AU754928B2 (en) 1997-10-06 2002-11-28 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2001078775A (ja) * 1999-09-14 2001-03-27 Kokuritsu Seishin Shinkei Center マクロファージ機能調節剤
US20040224306A1 (en) * 1999-11-30 2004-11-11 Frederich-Wilhelm Kuhne Evaluating and predicting clinical outcomes by gene expression analysis
US6685754B2 (en) 2001-03-06 2004-02-03 Alchemix Corporation Method for the production of hydrogen-containing gaseous mixtures
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Similar Documents

Publication Publication Date Title
JP2013525444A5 (enExample)
JP2012092110A5 (enExample)
JP2014515013A5 (enExample)
JP2015525757A5 (enExample)
JP2013509429A5 (enExample)
JP2013014622A5 (enExample)
JP2013032389A5 (enExample)
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
JP2012107014A5 (enExample)
BR112014000268A2 (pt) pirazolopiridinas com substituinte heteroarilo e utilização destas
JP2013520405A5 (enExample)
JP2012193216A5 (enExample)
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
JP2014530840A5 (enExample)
JP2013507408A5 (enExample)
EA201591957A1 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112015025675A2 (pt) derivados do tipo bisamida de ácido dicarboxílico, uso dos mesmos, composição farmacêutica à base dos mesmos, e métodos para produzir derivados do tipo bisamida de ácido dicarboxílico
JP2016530291A5 (enExample)
JP2013533867A5 (enExample)
JP2015509514A5 (enExample)
JP2012051888A5 (enExample)
JP2016538288A5 (enExample)
JP2015521598A5 (enExample)
JP2014518280A5 (enExample)